Softwr

Healthcare · head to head

DHIS2 vs Therapixel

DHIS2 logo

DHIS2

Healthcare

Open source health information platform run from the University of Oslo and used by national ministries

From
Free
Rated
-
Full reviewWebsite
Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only DHIS2 has a free tier, so it costs nothing to try first.
  • Each has a real cost: DHIS2 the licence is free and the implementation is not; national rollouts routinely cost hundreds of thousands of dollars in configuration, hosting, training and support, and budgets built on the word free fail immediately.; Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • They diverge on capability: DHIS2 covers Aggregate data reporting, Therapixel covers MammoScreen 2D.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which DHIS2 and Therapixel actually diverge.

Attributes where DHIS2 and Therapixel differ
AttributeDHIS2Therapixel
Starting priceFreeOn request
Pricing modelOpen source, no licence feequote
Free tierYesNo
PlatformsWeb, Android, Self-hosted, CloudWeb

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in DHIS2

  • Aggregate data reporting
  • Tracker
  • Android capture app
  • Dashboards and analytics
  • Metadata packages
  • Data quality tools
  • GIS mapping
  • Interoperability

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

What people use each for

The jobs each tool is most often brought in to do.

DHIS2

  • A ministry of health replacing paper monthly reporting from thousands of facilities with a national routine systemnot Therapixel
  • A donor-funded HIV or tuberculosis programme that must report standard indicators across several districtsnot Therapixel
  • A disease surveillance unit needing weekly case reporting with outbreak alerting and mappingnot Therapixel
  • An NGO running individual patient follow-up in a programme where facilities are frequently offlinenot Therapixel

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot DHIS2
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot DHIS2
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot DHIS2
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot DHIS2

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

DHIS2

  • The licence is free and the implementation is not; national rollouts routinely cost hundreds of thousands of dollars in configuration, hosting, training and support, and budgets built on the word free fail immediately.
  • HISP UiO introduced a Shared Services Fee in 2025, so organisations that depend on DHIS2 are now being asked for an annual contribution that did not previously exist in their plans.
  • Development funding comes from a small set of donors including Norad, the Global Fund and the Gates Foundation, which concentrates the platform's long-term direction in the priorities of those funders.
  • Implementation capability is concentrated in regional HISP groups, so a country whose local HISP group is overstretched has few alternative suppliers with equivalent expertise.
  • Analytics performance depends heavily on how metadata was designed at the outset, and a poorly structured initial configuration produces slow dashboards and bad indicator definitions that are painful to correct years later.

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Pricing, plan by plan

DHIS2

Free
  • DHIS2 softwareFree
    • BSD licence
    • All modules including Tracker
    • No user or facility limits
  • Shared Services Fee$undefined/year
    • Voluntary annual contribution introduced by HISP UiO
    • Funds shared global infrastructure and platform sustainability
    • Amount agreed with the HISP Centre
  • Implementation and support$undefined/year
    • Delivered by regional HISP groups or private implementers
    • Configuration, metadata design, hosting, training and support
    • Quoted per programme, commonly the dominant cost

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Which should you pick?

Choose DHIS2 if

  • You need aggregate data reporting.
  • You want to start without paying.
  • You work on Web, Android, Self-hosted, Cloud.
  • You also want tracker.
DHIS2 review

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Questions people ask

Is DHIS2 or Therapixel better?
Neither clearly leads. DHIS2 starts at Free and Therapixel at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, DHIS2 or Therapixel?
DHIS2 has a free tier; the other does not. Paid plans start at Free for DHIS2 and On request for Therapixel.
Does DHIS2 or Therapixel run on more platforms?
DHIS2 runs on Web, Android, Self-hosted, Cloud. Therapixel runs on Web.
Can I use DHIS2 for free?
Yes. DHIS2 has a free tier, so you can try it without paying. Therapixel starts at On request.
What is DHIS2 best used for?
DHIS2 is most often used for a ministry of health replacing paper monthly reporting from thousands of facilities with a national routine system, a donor-funded hiv or tuberculosis programme that must report standard indicators across several districts, a disease surveillance unit needing weekly case reporting with outbreak alerting and mapping, an ngo running individual patient follow-up in a programme where facilities are frequently offline. Of those, a ministry of health replacing paper monthly reporting from thousands of facilities with a national routine system and a donor-funded hiv or tuberculosis programme that must report standard indicators across several districts are not what Therapixel is typically brought in for.
What can DHIS2 do that Therapixel cannot?
DHIS2 covers Aggregate data reporting, Tracker, Android capture app, Dashboards and analytics. Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report.

Answered from the vendors’ own pages

DHIS2: Who owns and develops DHIS2?

The HISP Centre at the University of Oslo, funded by donors including Norad, the Global Fund, the Gates Foundation and Wellcome.

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

DHIS2: Is DHIS2 free?

The software is free under a BSD licence. Implementation, hosting, training and support are not, and are the dominant cost.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

DHIS2: What is the Shared Services Fee?

A voluntary annual contribution introduced by HISP UiO in 2025 to fund shared global infrastructure and long-term platform sustainability.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

DHIS2: Can I buy commercial support?

Yes, from regional HISP groups or private implementers such as Devotta, which is contracted by HISP UiO for core platform development and also works independently.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Share

Related pages

More on DHIS2

More on Therapixel

Keep looking

Other head to heads